The underlying philosophy of the Core remains a belief that validation of diagnosis is critical to clinical research into neurodegenerative diseases and that tissue-based studies are a critical complement to in vitro studies of the biologic process that underlying these diseases. By providing these two pillars to the clinical and scientific community, the Neuropathology Core is able to make a contribution to the amelioration of suffering associated with AD and related disorders.
The Specific Aims of the Neuropathology Coreare: 1. To establish an accurate neuropathological diagnosis on all brains submitted with standardized reporting, including clinicopathological correlation and interpretation of findings, to the Clinical Core, other treating physicians andfamilies; 2. To maintain a source of brain tissue and other samples for investigators studying AD and related disorders, through preparation of tissue in a standardized manner, including determination of RNAquality, with special consideration of investigators within the Massachusetts ADRC; 3. To work with the Clinical Core to develop, store and distribute DNA, cell lines, plasma and serum collected under the Clinical Core's Biomarkers Initiative; 4. To train diagnostic and experimental neuropathologists in the neuropathology of dementing disorders; and 5. To participate in cooperative ventures with other groups studying neurodegenerative diseases, both human and animal models, including other Alzheimer Centers (ADRCs &ADCs), NACC, NINDS- supported Udall Center, as well as other consortia and individual investigators. These broad goals, which are in continuity with the historical activities of the Neuropathology Core, will enhance the value of the collected brain tissue to individual investigators whose specific research projects depend upon receiving carefully prepared and examined tissue.

Public Health Relevance

Brain tissue is a critical resource for many important experiments that are defining the underlying pathology of Alzheimer disease and other neurodegenerative diseases. The ability to use the collect tissue in experiments is essential as new therapies and disease markers are developed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005134-29
Application #
8375450
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
29
Fiscal Year
2012
Total Cost
$220,542
Indirect Cost
$50,679
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Hopp, Sarah C; Lin, Yang; Oakley, Derek et al. (2018) The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. J Neuroinflammation 15:269
Xiong, Li; van Veluw, Susanne J; Bounemia, Narimene et al. (2018) Cerebral Cortical Microinfarcts on Magnetic Resonance Imaging and Their Association With Cognition in Cerebral Amyloid Angiopathy. Stroke 49:2330-2336
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Wegmann, Susanne; Eftekharzadeh, Bahareh; Tepper, Katharina et al. (2018) Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J 37:
Racine, Annie M; Brickhouse, Michael; Wolk, David A et al. (2018) The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment. Alzheimers Dement (Amst) 10:301-310
Bennett, Rachel E; Robbins, Ashley B; Hu, Miwei et al. (2018) Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A 115:E1289-E1298
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 966 publications